patients with postural orthostatic tachycardia syndrome diagnosis.

Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy

Whole blood will be retain for DNA extraction.

Postural Tachycardia Syndrome

Oral glucose tolerance test

Vanderbilt University Medical Center

Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome

POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND GASTROINTESTINAL SYMPTOMS: Contribution of Gastrointestinal Peptides

The plasma levels of GI peptides (GLP-1, GLP-2, PPY, glucagon, C-peptide, insulin) and their pattern of secretion after ingestion of 75 g glucose.

Gastric emptying time will be measured by acetaminophen absorption test after ingestion of 75 grams glucose.

The gastrointestinal symptoms will be evaluated by questionnaire after ingestion of 75 grams glucose.

Symptoms related to postural orthostatic tachycardia symptoms will be evaluated by specific questionnaire after ingestion of 75 grams glucose.

Cyndya Shibao

Assistant Professor

Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks

Placebo capsule containing Dicalcium Phosphate 500mg, BD

Diabetes

Fenugreek seeds extract

Placebo

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

Clinical Evaluation of Fenugreek Seed Extract In Patients With Type- 2 Diabetes: An Add-On Study

Reduction in fasting blood sugar levels (FBS) (mg/dL)

Reduction in post prandial blood sugar levels (mg/dL)

Chemical Resources

Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin

Group will receive placebo for 3 months in addition to their insulin

Type 1 Diabetes Mellitus

Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.

Linagliptin

Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.

Department of Endocrinology, PGIMER

Incretin Axis in Type 1 Diabetes Mellitus

Effect of Linagliptin on Incretin Axis in Type 1 Diabetes

Change in HbA1C in linagliptin group as compared to placebo group

Change in glycemic variability (CGMS indices) in linagliptin group as compared to placebo group

Change in insulin requirement in linagliptin group as compared to placebo group

Change in Area under the curve (AUC) of GLP1 during mixed meal test in linagliptin group as compared to placebo group

Change in Area under the curve (AUC) of glucagon during mixed meal test in linagliptin group as compared to placebo group

Sanjay K. Bhadada

Associate Professor

Postgraduate Institute of Medical Education and Research

Type 2 Diabetes Mellitus

form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

MP-513

Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day

Handok INC

Handok Pharmaceuticals CO. LTD

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

A Phase III Double-blind, Parallel Group, Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of MP-513 Monotherapy in Patients With Type 2 Diabetes Mellitus

peptidase/vômito

Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

Incretin Axis in Type 1 Diabetes Mellitus

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

O mais completo banco de dados de ervas medicinais apoiado pela ciência